Drug: Zeposia (ozanimod)

Manufacturer: Bristol Myers Squibb

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication:

• • treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • treatment of moderately-to-severely active ulcerative colitis in adults

Disease: multiple sclerosis, ulcerative colitis

Therapeutic Area: Gastroenterology, Neurology

Enrollment Form Link: N/A

Phone Number: 1-833-ZEPOSIA (1-833-937-6742)

Fax Number: 1-833-727-7701

Product Website: zeposia.com